Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page
- Check3 days agoChange DetectedA new Revision: v3.6.4 tag was added and several unrelated topics/links along with an older Revision tag were removed, indicating a metadata cleanup rather than changes to the trial data.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded related topics: Lung cancer, related topics, and MedlinePlus Genetics to the study record, improving contextual linkage to related resources. The change enhances navigation and discoverability without altering the study's content, eligibility criteria, or results.SummaryDifference0.1%

- Check25 days agoChange DetectedA new revision entry 'Revision: v3.6.3' was added to the site's revision log, while older items including 'Lung cancer', 'related topics:', 'MedlinePlus Genetics', and 'Revision: v3.6.2' were removed.SummaryDifference0.2%

- Check32 days agoChange DetectedAdded Lung cancer and related topics with a MedlinePlus Genetics link to the page's information section. The revision tag was updated to v3.6.2, replacing the previous v3.6.0.SummaryDifference0.2%

- Check40 days agoChange DetectedThe page's MedlinePlus related topics section has had items removed, including Lung cancer and MedlinePlus Genetics, along with the related topics header.SummaryDifference0.1%

- Check47 days agoChange DetectedRecruitment status shows enrollment is closed, and new sections like How to Read a Study Record, Common Questions, How to Join a Study, and related topics have been added to guide users through the study information.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.